Influenza A (H5N1) Virus monovalent vaccine

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

InfluenzaInfluenza Vaccines

Phase 2

A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64

CompletedNCT00695669

GlaxoSmithKlineInfluenza

Start: 2008-06-05End: 2009-01-08Updated: 2018-07-31

Phase 3

Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age

CompletedNCT01310413

GlaxoSmithKlineInfluenza, Influenza Vaccines

Start: 2011-03-07End: 2014-01-26Updated: 2021-11-01

Related Papers

Reactogenicity and safety of AS03 <sub>B</sub> -adjuvanted H5N1 influenza vaccine in children: an open-label, one-way, crossover trial

Asian Biomedicine2017-08-01

AS03B-Adjuvanted H5N1 Influenza Vaccine in Children 6 Months Through 17 Years of Age: A Phase 2/3 Randomized, Placebo-Controlled, Observer-Blinded Trial

The Journal of Infectious Diseases2014-10-0624 citations

Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03(A)-adjuvanted vaccination in adults.

2011-08-0119 citations